PYC Therapeutics Future Growth
Future criteria checks 2/6
PYC Therapeutics is forecast to grow earnings and revenue by 25.5% and 30.1% per annum respectively. EPS is expected to grow by 31.3% per annum. Return on equity is forecast to be -43.2% in 3 years.
Key information
25.5%
Earnings growth rate
31.3%
EPS growth rate
Biotechs earnings growth | 16.2% |
Revenue growth rate | 30.1% |
Future return on equity | -43.2% |
Analyst coverage | Low |
Last updated | 07 Mar 2024 |
Recent future growth updates
No updates
Recent updates
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Apr 10Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully
Jul 03Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Jan 25Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Jul 31We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate
Mar 28Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)
Feb 20Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?
Jan 26What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition
Dec 22We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth
Nov 17Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 33 | -7 | -21 | -20 | 2 |
6/30/2025 | 8 | -34 | -19 | -18 | 2 |
6/30/2024 | 8 | -31 | -18 | -18 | 2 |
12/31/2023 | 21 | -22 | -20 | -19 | N/A |
9/30/2023 | 19 | -22 | -22 | -22 | N/A |
6/30/2023 | 16 | -23 | -25 | -24 | N/A |
3/31/2023 | 15 | -23 | -26 | -25 | N/A |
12/31/2022 | 14 | -24 | -26 | -26 | N/A |
9/30/2022 | 15 | -19 | -24 | -24 | N/A |
6/30/2022 | 16 | -14 | -22 | -22 | N/A |
3/31/2022 | 13 | -15 | -18 | -17 | N/A |
12/31/2021 | 9 | -17 | -14 | -13 | N/A |
9/30/2021 | 6 | -17 | -13 | -12 | N/A |
6/30/2021 | 3 | -18 | -12 | -12 | N/A |
3/31/2021 | 3 | -15 | -11 | -11 | N/A |
12/31/2020 | 2 | -12 | -10 | -10 | N/A |
9/30/2020 | 2 | -9 | -8 | -8 | N/A |
6/30/2020 | 2 | -7 | -6 | -6 | N/A |
3/31/2020 | 1 | -6 | -6 | -6 | N/A |
12/31/2019 | 0 | -5 | -6 | -6 | N/A |
9/30/2019 | 0 | -5 | -6 | -6 | N/A |
6/30/2019 | N/A | -4 | -6 | -5 | N/A |
3/31/2019 | 0 | -4 | -4 | -4 | N/A |
12/31/2018 | 0 | -5 | -3 | -3 | N/A |
9/30/2018 | 0 | -6 | -5 | -5 | N/A |
6/30/2018 | 0 | -7 | -7 | -7 | N/A |
3/31/2018 | 0 | -6 | -5 | -5 | N/A |
12/31/2017 | 0 | -5 | -3 | -3 | N/A |
9/30/2017 | 1 | -3 | N/A | -3 | N/A |
6/30/2017 | 3 | -2 | N/A | -2 | N/A |
3/31/2017 | 3 | -3 | N/A | -4 | N/A |
12/31/2016 | 3 | -4 | N/A | -6 | N/A |
9/30/2016 | 1 | -4 | N/A | -5 | N/A |
6/30/2016 | 0 | -4 | N/A | -3 | N/A |
3/31/2016 | 0 | -4 | N/A | -2 | N/A |
12/31/2015 | 0 | -4 | N/A | -1 | N/A |
9/30/2015 | 0 | -3 | N/A | -2 | N/A |
6/30/2015 | 1 | -3 | N/A | -2 | N/A |
3/31/2015 | 1 | -3 | N/A | -3 | N/A |
12/31/2014 | 1 | -3 | N/A | -4 | N/A |
9/30/2014 | 1 | -3 | N/A | -4 | N/A |
6/30/2014 | 1 | -3 | N/A | -3 | N/A |
3/31/2014 | 1 | -3 | N/A | -3 | N/A |
12/31/2013 | 1 | -3 | N/A | -3 | N/A |
9/30/2013 | 1 | -3 | N/A | -2 | N/A |
6/30/2013 | 1 | -3 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PYC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PYC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PYC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PYC's revenue (30.1% per year) is forecast to grow faster than the Australian market (4.7% per year).
High Growth Revenue: PYC's revenue (30.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PYC is forecast to be unprofitable in 3 years.